Trial Profile
A Phase III Multicenter, Open-Label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Acronyms RATE
- Sponsors Genentech
- 22 Dec 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 11 Dec 2011 Status changed from active, no longer recruiting to completed; results have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology .
- 23 Nov 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.